Pfizer shifts to post-pandemic growth

Pfizer’s shares are down 45% in the past year due to lower demand for its COVID-19 treatments as the pandemic eases. However, new products from its acquisition of Seagen and its high research spending, generally, should spur long-term growth and your dividends.
PFIZER INC. $28 is… Read More

Pfizer ready for post-COVID sales

Pfizer recently cut its outlook for 2023 due to declining demand for its COVID-19 vaccines and treatments. However, the company is using the huge profits it earned on those products to buy other drugmakers with promising products.
We feel these moves, as well as Pfizer’s own… Read More